How Does Novo Nordisk Make its Money?
Novo Nordisk is a Danish pharmaceutical company and the world leader in diabetes care and obesity treatment. The company has been transformed by the explosive success of its GLP-1 receptor agonist drugs — Ozempic (for type 2 diabetes) and Wegovy (for obesity/weight management) — which have become the most in-demand medicines in the world.
Founded in 1923, Novo Nordisk built its business on insulin and has been the global market leader in diabetes care for decades. The GLP-1 revolution has taken the company to an entirely new level, with semaglutide (the active ingredient in Ozempic and Wegovy) demonstrating benefits not just for blood sugar control and weight loss, but potentially for cardiovascular disease, kidney disease, fatty liver disease, and sleep apnea.
Revenue Breakdown
| Product/Category | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Ozempic | DKK 140.0B | DKK 99.0B | +41.4% |
| Wegovy | DKK 51.0B | DKK 31.3B | +62.9% |
| Other GLP-1 (Victoza, Rybelsus) | DKK 22.0B | DKK 23.5B | -6.4% |
| Insulin (Tresiba, NovoRapid, etc.) | DKK 53.0B | DKK 51.0B | +3.9% |
| Other Diabetes & Obesity | DKK 12.0B | DKK 10.5B | +14.3% |
| Rare Disease (Hemophilia, etc.) | DKK 12.5B | DKK 12.0B | +4.2% |
| Total Revenue | DKK 290.4B (~$42B) | DKK 232.3B (~$34B) | +25.0% |
Ozempic — 48% of Revenue
A once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes. Ozempic has become one of the best-selling drugs in pharmaceutical history, with revenue growing 41% year-over-year. The drug is also widely prescribed off-label for weight loss, though its official indication is diabetes. Ozempic’s success is driven by its efficacy (average 15% body weight reduction), favorable cardiovascular outcomes, and massive direct-to-consumer advertising.
Wegovy — 18% of Revenue
The same semaglutide molecule as Ozempic but dosed and approved specifically for chronic weight management. Wegovy is the first drug to demonstrate that pharmacological weight loss reduces heart attack and stroke risk by 20% (the SELECT trial). This indication has expanded the addressable market enormously — an estimated 100+ million adults in the U.S. alone could qualify. Wegovy supply has been constrained since launch, and Novo Nordisk is investing billions to expand manufacturing capacity.
Insulin — 18% of Revenue
Novo Nordisk’s legacy business and still a significant revenue contributor. Key products include Tresiba (long-acting), NovoRapid (rapid-acting), and the new once-weekly insulin icodec (Awiqli). The insulin portfolio provides a stable base while GLP-1 products drive growth.
Rare Disease — 4% of Revenue
Hemophilia treatments (NovoSeven, Esperoct) and growth hormone disorders. A smaller but profitable business.
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | DKK 290.4B | DKK 232.3B |
| Cost of Goods Sold | DKK 66.4B | DKK 51.6B |
| Gross Profit | DKK 224.0B | DKK 180.7B |
| Operating Expenses | DKK 103.0B | DKK 82.0B |
| Operating Income | DKK 121.0B | DKK 98.7B |
| Net Income | DKK 91.0B (~$13.2B) | DKK 83.7B (~$12.1B) |
Key Financial Metrics
- Gross Margin: 77.1% — Outstanding, reflecting the high value of patented biological medicines. Manufacturing biologics is complex but the pricing power is enormous.
- Operating Margin: 41.7% — Among the highest in all of pharma. Novo Nordisk’s pricing authority and scale in GLP-1 production drive extraordinary profitability.
- Revenue Growth: +25.0% — Exceptional for a company of this size. Growth was constrained by manufacturing capacity rather than demand — the real demand for semaglutide likely exceeds what Novo Nordisk can currently produce.
- Capex: DKK 40B+ — Novo Nordisk is investing aggressively in manufacturing expansion, including filling/finishing capacity and API (active pharmaceutical ingredient) production. The capex bill reflects the scale of the GLP-1 opportunity.
What to Watch
- GLP-1 competition — Eli Lilly’s tirzepatide (Mounjaro/Zepbound) is the primary competitor and has shown slightly greater weight loss in some trials. The GLP-1 market is likely big enough for both, but market share dynamics between Novo Nordisk and Lilly will significantly impact revenue.
- Manufacturing capacity — Supply has been the binding constraint on Wegovy and Ozempic revenue. Novo Nordisk’s ability to scale manufacturing will directly determine growth trajectory for the next 2-3 years.
- Insurance coverage expansion — Medicare, Medicaid, and private insurers are gradually expanding GLP-1 coverage for obesity. Every coverage expansion dramatically increases the accessible patient population.
- Oral semaglutide — Rybelsus is the oral form of semaglutide. Higher-dose oral semaglutide in development could be a game-changer by eliminating the need for injections, making the drug more accessible.
- Next-generation molecules — Novo Nordisk has amycretin (a next-gen molecule showing ~22% weight loss) and CagriSema (combined semaglutide + cagrilintide) in clinical trials. These could sustain growth beyond semaglutide’s eventual patent expiration.